Reneo Pharmaceuticals Inc

General ticker "RPHM" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $50.9M

Reneo Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -37.7%.

Estimated limits based on current volatility of 4.0%: low 16.67$, high 18.05$

Factors to consider:

  • Earnings for 6 months up through Q2 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [30.38$, 81.70$]
  • 2024-12-30 to 2025-12-30 estimated range: [26.50$, 72.89$]

Financial Metrics affecting the RPHM estimates:

  • Negative: Operating Income to Revenue ratio of -1.00 <= 0.01
  • Negative: Non-GAAP EPS of -2.52 <= 0.11
  • Negative: Operating Cash Flow per share of -2.08 <= 0.22
  • Negative: negative Net Income
  • Negative: Industry Operating Cash Flow per share (median) of -1.60 <= 0.31
  • Negative: Industry Earnings per Price (median) of -0.24 <= 0.01

Similar symbols

Short-term RPHM quotes

Long-term RPHM plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $39.82MM $53.85MM $83.08MM
Operating Income $-39.82MM $-53.85MM $-83.08MM
Non-Operating Income $0.05MM $1.89MM $5.69MM
R&D Expense $28.17MM $37.70MM $56.09MM
Income(Loss) $-39.77MM $-51.95MM $-77.39MM
Profit(Loss) $-39.77MM $-51.95MM $-77.39MM
Stockholders Equity $147.21MM $99.97MM $88.61MM
Assets $154.02MM $108.18MM $107.44MM
Operating Cash Flow $-37.98MM $-47.36MM $-63.68MM
Investing Cash Flow $-23.38MM $-57.84MM $10.52MM
Financing Cash Flow $132.41MM $0.47MM $60.87MM
Earnings Per Share* $-2.19 $-2.04 $-2.52

* EPS are Split Adjusted, recent splits may be reflected with a delay.